Back to Hematology
HematologyvMalcovati 2007Evidence-Based

WPSS (WHO classification-based Prognostic Scoring System) for Myelodysplastic Syndrome

Assesses prognosis of patients with myelodysplastic syndrome (MDS) based on WHO morphological classification, cytogenetics, and transfusion requirement. The WPSS provides dynamic prognostic assessment throughout disease course and stratifies patients into five risk groups.

Clinical Input Parameters

categorical
categorical
categorical
Clinical Assessment
Awaiting Parameters
wpss score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The WPSS (WHO classification-based Prognostic Scoring System) for Myelodysplastic Syndrome is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

WPSS Score = WHO Category Score + Karyotype Score + Transfusion Requirement Score

Clinical Pearls & Practice Notes

  • WPSS is dynamic and can be recalculated throughout disease course
  • Unlike IPSS, WPSS can be applied at any time during follow-up
  • Regular transfusion requirement defined as ≥1 RBC transfusion every 8 weeks over 4 months
  • Intermediate cytogenetic risk includes all abnormalities not classified as good or poor
  • Score provides both survival and leukemic transformation risk assessment

Evidence & Literature Citations

  1. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-3510. doi: 10.1200/JCO.2006.08.5696
  2. Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011;96(10):1433-1440. doi: 10.3324/haematol.2011.044602
  3. Della Porta MG, Tuechler H, Malcovati L, et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). Leukemia. 2015;29(7):1502-1513. doi: 10.1038/leu.2015.55

Score Interpretation Ranges

Very Low Risk0 – 0 pts

Excellent prognosis

Low Risk1 – 1 pts

Good prognosis

Intermediate Risk2 – 2 pts

Moderate prognosis

High Risk3 – 4 pts

Poor prognosis

Very High Risk5 – 6 pts

Very poor prognosis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.